Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. (Q47832226)

6 February 2018

title

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. (English)

1 reference

6 February 2018

4

Umesh D Parashar

1 reference

6 February 2018

3

Jacqueline Tate

1 reference

6 February 2018

Deborah E Atherly

series ordinal

1

object named as

Deborah E Atherly

1 reference

6 February 2018

author name string

Kristen D C Lewis

series ordinal

2

1 reference

6 February 2018

Richard D Rheingans

series ordinal

5

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 April 2012

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

30 Suppl 1

1 reference

6 February 2018

page(s)

A7-14

1 reference

6 February 2018

Global, regional, and national causes of child mortality in 2008: a systematic analysis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Global mortality associated with rotavirus disease among children in 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Rotavirus vaccines in Belgium: policy and impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Childhood diarrhea deaths after rotavirus vaccination in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Effect of rotavirus vaccination on death from childhood diarrhea in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Cost-effectiveness of rotavirus vaccination in peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Global Illness and Deaths Caused by Rotavirus Disease in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Antibody response of infants in tropics to five doses of oral polio vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Immunisation and herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.096

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.12.096

1 reference

6 February 2018

PubMed ID

22520139

1 reference

6 February 2018